Access Biotechnology

Access Biotechnology accounts for 18 tracked companies with verified cap-table data, 18 of which disclose round sizes totalling $4B. The median disclosed raise is $140M, and the largest is ACELYRIN at $758M, ahead of Spyre Therapeutics ($644M) and Hemab ($537M).

The names that recur most often on these portfolio cap tables are Access Biotechnology (18 companies), Atlas Venture (6 companies), OrbiMed (6 companies), RA Capital Management (3 companies), Sanofi Ventures (3 companies), VenBio Partners (2 companies). By latest disclosed round, the market skews Series B (6), Series A (6), Series C (3), Growth (2).

• Companies tracked: 18
• Disclosed funding total: $4B across 18 companies
• Median disclosed raise: $140M
• Largest raise: ACELYRIN — $758M
• Stage mix: Series B 6 · Series A 6 · Series C 3 · Growth 2
• Most recent dated round: 2026-05-01

Best funded Access Biotechnology companies

1. ACELYRIN — $758M (latest: Series C)
2. Spyre Therapeutics — $644M (latest: Growth)
3. Hemab — $537M (latest: IPO)
4. Ventus Therapeutics — $370M (latest: Series C)
5. Escient Pharmaceuticals — $238M (latest: Series C)
6. Halda Therapeutics — $202M (latest: Series B)
7. Upstream Bio — $200M (latest: Series A)
8. Disc Medicine — $153M (latest: Series B)
9. Draig Therapeutics — $140M (latest: Series A)
10. DTx Pharma — $114M (latest: Series B)
11. Matchpoint Therapeutics — $100M (latest: Series A)
12. GRO Biosciences — $91M (latest: Series B)
13. VYNE Therapeutics — $88M (latest: Growth)
14. Eliem Therapeutics — $80M (latest: Series A)
15. Curie Therapeutics — $75M (latest: Series A)

Access Biotechnology — related firms and companies (56)

• ACELYRIN
• Spyre Therapeutics
• Hemab
• Ventus Therapeutics
• Escient Pharmaceuticals
• Halda Therapeutics
• Upstream Bio
• Disc Medicine
• Eliem Therapeutics
• Investors like Slow Ventures
• Investors like Point72 Ventures
• Investors like BoxGroup
• Investors like SoftBank Vision Fund
• Investors like Tiger Global Management
• Investors like Amplify Partners
• Curie Therapeutics
• Investors like Vine Ventures
• Investors like IVP
• Investors like Recursive Ventures
• Investors like Fika Ventures
• Investors like Plug and Play
• Investors like RRE Ventures
• Recludix Pharma
• Investors like Alexandria Venture Investments
• Investors like Google Ventures
• Draig Therapeutics
• Investors like DCVC
• Investors like QED Investors
• Investors like Foundation Capital
• CuraSen Therapeutics
• Investors like Notable Capital
• Investors like Expansion Venture Capital
• DTx Pharma
• Investors like Felicis
• Investors like Elemental Impact
• Investors like Accel
• Trefoil Therapeutics
• Investors like Liquid 2 Ventures
• Investors like Peak XV Partners
• Matchpoint Therapeutics
• Investors like Coinbase
• Investors like Uncork Capital
• Investors like Amino Capital
• Access Biotechnology co-investors 2026
• Investors like Andreessen Horowitz
• Investors like Scale Venture Partners
• GRO Biosciences
• Investors like Motivate Venture Capital
• Investors like First Round Capital
• Investors like FirstMark
• Investors like Access Biotechnology
• Investors like StepStone Group
• Investors like Bain Capital Ventures
• VYNE Therapeutics
• Investors like Maveron
• Investors like Trinity Ventures

Access Biotechnology alternatives · All research reports